The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19.

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

This is what it looks like when disinformation doctors pretend to value data and science to further their true objective, ...

Explore last week's key healthcare market trends, top gainers & losers, major deals, Trump's tariff plans, FDA approvals, and significant legal updates.

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago. Indeed, if you axed Moderna off your watchlist after the ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory ...

Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at ...

Moderna said it will engage with regulators on filing submissions for the flu vaccine candidate, mRNA-1010, which was tested in a study population that included 40,805 adults aged 50 years and older.